What a Headache: California Regulators Want To Label Acetaminophen a Carcinogen
The science is unsettled, and a new warning label would probably just confuse people.
The science is unsettled, and a new warning label would probably just confuse people.
The Right to Try movement, which recently became federal law, allows doctors to prescribe experimental treatments that haven't been approved for sale by regulators.
When and wherever public health conflicted with personal freedom, Gottlieb advocated for the former.
Plus: Tumblr porn filters catch company's own examples of permitted content and how the GOP learned to love bailouts.
"Our vision for a new, more transparent drug-pricing system does not rely on voluntary action," says HHS Secretary Alex Azar.
Plus: Parkour robots, price transparency for drugs, and Hillary Clinton defending Bill over the Lewinsky affair
Initiatives to curb drug-maker influence have endangered medical workers, patients, and the healthcare system.
He has been a Democrat, a Republican, a lobbyist, and a cancer survivor. Now he wants to end the war on weed.
It's still not clear whether pharmaceutical companies will work with patients outside the FDA's supervision.
From ripping families apart to nominating a torture-enabler as CIA director, the administration is calling the GOP's bluff, Reason editors argue.
Change drug prices by changing the market.
The FDA chief's mixed, moderate record has surprised both his champions and his critics.
Making drug-company shareholders foot the bill for a public health crisis is flaky and counterproductive.
The drug regulator's clinical trials process for approving drugs needs a complete overhaul.
The change would put D.C. in line with a rapidly rising number of states allowing pharmacist-prescribed oral contraceptives.
Do the pain relief benefits of prescription opioids outweigh their addiction risks?
What will really keep drug (and any other) prices lower? Competition.
Reason editors talk immigration, affirmative action, and why the "Pharma Bro" witch hunt should concern everyone.
Senate approves bill giving some earlier access to treatment.
The pharmaceutical market is anything but free at present.
Make pharmaceutical competition great again.
Contrary to what The New York Times claims, the outcry over EpiPen prices has made them lower.
Not a radical reformer, but clearly understands how overregulation is slowing medical innovation
Understands how over-regulation is slowing down innovation in medicines and foods
Americans would save some money now, but at the long-run cost of sicker and shorter lives
The unintended consequences to Americans' lives and health would be substantial and bad
Slashing the restraints on the agency's slow and burdensome process.
A Reason investigation uncovers how cops, prosecutors, and lobbyists conspired to restrict a promising cannabis-derived seizure treatment.
At Planned Parenthood clinics, 43 percent of all abortions are now drug-induced, not surgical.
As if fentanyl's public relations aren't bad enough.
What happens when cancer doctors, psychologists, and drug developers can't rely on each other's research?
Ballot box is the wrong place to debate drug-price intricacies, in California or anywhere else.
"Right to try" laws offer hope for people trying to save their own lives.
The freedom to set prices free of government coercion makes for better newspapers and better medicine.
The vast reach of government as a payer for health care means that drug companies are to a large degree government contractors, and patients are suffering.
Dave Huntley was a father, husand, & triathlete who contracted Lou Gehrig's Disease. But the FDA was his biggest foe.
Modafinil is "one of the most promising neuroenhancers to date"-and still a controlled substance in the U.S.
Slaps pharmaceutical company with warning letter.
Subsidized birth control pills for some women shouldn't come at the expense of easing access restrictions for all.
Missouri, like many states, is secretive about the drugs it uses in executions.
Do you care about free minds and free markets? Sign up to get the biggest stories from Reason in your inbox every afternoon.
This modal will close in 10